Singulair's Shadow: The Black Box Warning and the Hidden Toll of Neuropsychiatric Risks
Picture a young mother, her mornings once filled with the simple joy of watching her six-year-old chase butterflies in the backyard, now shattered by a frantic call from school. "He's not himself," the teacher says, voice trembling. Aggression flares where curiosity once bloomed; nightmares haunt sleep that should be peaceful. Desperate for relief from his persistent asthma wheezes, she'd turned to Singulair—montelukast, the once-celebrated pill promising easier breaths without steroids' weight. But in the quiet aftermath of a pediatrician's grim diagnosis of behavioral changes, she learns of the drug's dark underbelly: a black box warning etched into its label like a scar, cautioning against neuropsychiatric storms that can rage from irritability to the unthinkable—suicide. Singulair, manufactured by Merck, entered the U.S. market in 1998 as a leukotriene receptor antagonist, a novel class targeting asthma and allergy inflammation at its chemical roots. ...